Am J Transplant, Volume 17, Suppl 3 Archives - Page 24 of 181 - ATC Abstracts

2017 American Transplant Congress
Acute Cellar Rejection and Long-Term Graft Survival in Pediatric Kidney Transplant Recipients.
A. Massie, J. Garonzik-Wang, N. Desai, D. Segev.
JHU, Baltimore
The association between acute cellular rejection and long-term graft loss among pediatric kidney transplant recipients has not been quantified.Methods: Using SRTR data 2005-2015 and Cox…
2017 American Transplant Congress
Compartmental Infiltration of Kidney Allograft with Monocyte-Macrophage Subtypes Defines the Type of Rejection.
T. van den Bosch,¹ M. Clahsen-van Groningen,² F. Rezaee,³ D. Hesselink,¹ D. Nieboer,⁴ E. Steyerberg,⁴ C. Baan,¹ A. Rowshani.¹
¹Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands; ²Pathology, Erasmus University Medical Center, Rotterdam, Netherlands; ³Gastroenterology, Erasmus University Medical Center, Rotterdam, Netherlands; ⁴Public Health, Erasmus University Medical Center, Rotterdam, Netherlands
Purpose: Rejection significantly worsens the graft function and survival. We studied monocyte-macrophage compartmental infiltration of 62 kidney transplant biopsies with diagnosis of: acute antibody mediated…
2017 American Transplant Congress
Delayed Tolerance Induction Protocol for Vascularized Composite Allografts in Non-Human Primates: The Immunomodulatory Effect of Donor Bone Marrow Transplantation Does Not Prevent the Development of Chronic Rejection in the Absence of Durable Mixed Chimerism.
Z. Ng, A. Lellouch, A.-R. Gama, I. Schol, I. Rosales, R. Colvin, L. Geoghegan, J. Kurtz, C. Cetrulo.
Massachusetts General Hospital, Boston, MA
PURPOSE: Donor bone marrow transplantation (DBMT) has been investigated in experimental and clinical vascularized composite allotransplantation (VCA). With longer-term follow-up, reports of chronic VCA rejection…
2017 American Transplant Congress
The Role of Natural Killer Cells in Recognition and Killing of Stem Cells and Stem Cell-Derived Hepatoblasts.
T. Cisneros, D. Dillard, M. Castro, J. Arredondo-Guerrero, S. Krams, C. Esquivel, O. Martinez.
Surgery, Stanford University School of Medicine, Stanford, CA
The generation of stem cell-derived hepatocytes holds promise as a cell-based treatment for liver disease. However, the immune response to stem cell-derived grafts is poorly…
2017 American Transplant Congress
Preceeding the Rejection: Clinical Results of a Saliva Test After Renal Transplantation.
D. Abendroth,¹ M. Marzinzig,¹ M. Stangl.²
¹Dept. of Surgery, University of Ulm, Ulm, Germany; ²Dept. of Visceral and Transplant Surgery, Ludwigs-Maximilians-Universität, Munich, Germany
Introduction There remains a need for biomarker in transplantation for monitoring and early identification of rejection episodes (R). We developed a colorimetric assay to detect…
2017 American Transplant Congress
Direct Acting Antiviral Drugs Are Highly Effective in Hepatitis C (HCV) Patients with End Stage Renal Disease (ESKD) and Advanced Liver Disease (ALD).
J. Korula, T. Shah, E. Ranger, E. Barba, D. Vu, R. Naraghi.
Multi Transplant Organ Center, St Vincent Medical Center, Los Angeles, CA
Reports of efficacy of Direct Acting Antiviral drugs (DAA) > 90% in treatment of chronic HCV genotype 1, [GT1, 12 wk Sustained Viral Response (SVR12)]…
2017 American Transplant Congress
Treating Hepatitis C+ Patients Before or After Kidney Transplantation: A Medical Decision Analysis.
B. Kiberd,¹ K. Tennankore,¹ K. Doucette.²
¹Medicine, Dalhousie University, Halifax, NS, Canada; ²Medicine, University of Alberta, Edmonton, AB, Canada
Some have recommended that HCV+ kidney wait list patients delay HCV treatment with direct acting antiviral agents (DAAs) with the option of receiving an HCV+/HCV-…
2017 American Transplant Congress
The Benefits of Pancreas After Kidney (PAK) Transplantation.
M. Curry,¹ J. Odorico,² J. Fridell.³
¹Research, UNOs, Richmond, VA; ²Department of Surgery, University of Wisconsin, Madison, WI; ³Department of Surgery, Indiana University, Indianpolis, IN
Background: PAK transplantation has been perceived as inferior to Simultaneous Pancreas and Kidney (SPK) transplantation with respect to patient and pancreas (PA) allograft survival. However,…
2017 American Transplant Congress
Eight Year Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients.
J. Leventhal,¹ J. Galvin,¹ J. Mathew,¹ L. Gallon,¹ D. Stare,¹ A. Sweeney,¹ J. Miller,¹ M. Abecassis,¹ S. Ildstad.²
¹Northwestern University, Chicago; ²U of Louisville, Louisville
36 subjects have been transplanted in a phase 2 protocol (IDE 13947) to induce tolerance in recipients of living donor renal allografts (KTx). The protocol…
2017 American Transplant Congress
Designing a Novel Selective Immunoproteasome Inhibitor Reveals a Critical Role of the IP and STAT5 Pathway in Regulating T Cell Exhaustion and Promoting Long Term Heart Allograft Acceptance.
S. Routray, E. Karreci, M. Uehara, J. Assaker, A. Mihali, S. Eskandari, L. Riella, R. Abdi, Y. Kawano, C. Nathan, G. Lin, J. Azzi.
Transplant Research Center, Harvard Medical School, Boston, MA; Microbiology and Immunology, Weill Cornell Medicine, New York, NY
Constitutive proteasomes (c-20S) are ubiquitously expressed cellular proteases that degrade polyubiquitinated proteins and regulate cell functions. Immunoproteasomes (IP or i-20S) are primarily expressed in immune…